Guardant Health struck a multi‑year deal with Merck to provide liquid and tissue biopsy assays to help enroll patients in Merck’s global clinical studies. The agreement lets Merck deploy Guardant’s circulating tumor DNA and tissue‑based testing across trials to accelerate biomarker screening and reduce enrollment friction for molecularly defined cohorts. The partnership reflects growing industry reliance on centralized genomic testing to streamline trial recruitment and to support adaptive, biomarker‑driven designs. Guardant gains a strategic buyer while Merck secures diagnostic capacity to scale its oncology development programs worldwide.